Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic β-cell glucose metabolism and insulin secretion

Journal of Endocrinology

Volumn 189, Issue 2, 2006, Pages 301-310

  Patterson, S ^a   Flatt, P R ^a   Brennan, L ^b   Newsholme, P ^b   McClenaghan, N H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOISOCAPROIC ACID; ADENYLATE CYCLASE; ALANINE; ARGININE; CALCIUM ION; CARBACHOL; CHOLECYSTOKININ OCTAPEPTIDE; FORSKOLIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; GLUTAMIC ACID; HOMOCYSTEINE; INSULIN; NEUROTRANSMITTER; PHORBOL 13 ACETATE 12 MYRISTATE; POTASSIUM CHLORIDE; PROTEIN KINASE C; TOLBUTAMIDE; TRICARBOXYLIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; EXPOSURE; GLUCOSE METABOLISM; INHIBITION KINETICS; INSULIN RELEASE; METABOLIC SYNDROME X; NONHUMAN; NUTRIENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RISK FACTOR;

ALANINE; ARGININE; CALCIUM; CARBACHOL; CLONE CELLS; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; GASTROINTESTINAL HORMONES; GLUCOSE; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; KETO ACIDS; METABOLIC SYNDROME X; POTASSIUM CHLORIDE; TETRADECANOYLPHORBOL ACETATE; TOLBUTAMIDE;

EID: 33646820015     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06537     Document Type: Article

References (45)

1. Ashcroft FM & Rorsman P 2004 Molecular defects in insulin secretion in type-2 diabetes. Reviews in Endocrine and Metabolic Disorders 5 135-142.
2. Ashcroft FM, Ashcroft SJ & Harrison DE 1987 Effects of 2-ketoisocaproate on insulin release and single potassium channel activity in dispersed rat pancreatic beta-cells. Journal of Physiology 385 517-529.
3. Ashfield R, Gribble FM, Ashcroft SJ & Ashcroft FM 1999 Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. Diabetes 48 1341-1347.
4. Becker A, Kostense PJ, Bos G, Heine RJ, Dekker JM, Nijpels G, Bouter LM & Stehouwer CD 2003 Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. Journal of Internal Medicine 253 293-300.
5. Best L, Lebrun P, Saceda M, Garcia-Morales P, Hubinont C, Juvent M, Herchuelz A, Malaisse-Lagae F, Valverde I & Malaisse WJ 1984 Impairment of insulin release by methylation inhibitors. Biochemical Pharmacology 33 2033-2039.
6. Blennow G, Folbergrova J, Nilsson B & Siesjo BK 1979 Cerebral metabolic and circulatory changes in the rat during sustained seizures induced by D,L-homocysteine. Brain Research 179 129-146.
7. Blundell G, Jones BG, Rose FA & Tudball N 1996 Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 122 163-172.
8. Bostom AG & Lathrop L 1997 Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney International 52 10-20.
9. Brennan L, Shine A, Hewage C, Malthouse JP, Brindle KM, McClenaghan N, Flatt PR & Newsholme P 2002 A nuclear magnetic resonance-based demonstration of substantial oxidative L-alanine metabolism and L-alanine-enhanced glucose metabolism in a clonal pancreatic β-cell line. Diabetes 51 1714-1721.
10. Buysschaert M, Dramais AS, Wallemacq PE & Hermans MP 2000 Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23 1816-1822.
11. Dalton ML, Gadson PF, Wrenn RW & Rosenquist TH 1997 Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB Journal 11 703-711.
12. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LAJ & Blom HJ 2002 Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacological Reviews 54 599-618.
13. Dixon G, Nolan J, McClenaghan NH, Flatt PR & Newsholme P 2004 Arachidonic acid, palmitic acid and glucose are important for the modulation of clonal pancreatic beta cell insulin secretion, growth and functional integrity. Clinical Science 106 191-199
14. Drzewoski J, Czupryniak L, Chwatko G & Bald E 2000 Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes, Nutrition and Metabolism 13 319-324.
15. 2+ measurements. Biochimica et Biophysica Acta 1055 157-164.
16. Flatt PR & Bailey CJ 1981 Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 573-577.
17. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK & Robertson RP 1999 In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 48 1995-2000.
18. Herrmann W 2001 The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clinical Chemistry and Laboratory Medicine 39 666-674.
19. Hultberg B 2004 Extracellular concentration of homocysteine in human cell lines is influenced by specific inhibitors of cyst(e)ine transport. Clinical Chemistry and Laboratory Medicine 42 378-383.
20. Hutton JC, Sener A & Malaisse WJ 1980 Interaction of branched chain amino acids and keto acids upon pancreatic islet metabolism and insulin secretion. Journal of Biological Chemistry 255 7340-7346.
21. Kim WK & Pae YS 1996 Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neuroscience Letters 216 117-120.
22. Kulkarni RN 2004 The islet β-cell. International Journal of Biochemistry and Cell Biology 36 365-371.
23. Ling Z & Pipeleers DG 1996 Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. Journal of Clinical Investigation 98 2805-2812.
24. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR & Stamler JS 1997 Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. PNAS 94 5923-5928.
25. Lowry OH, Rosebrough NJ, Farr AL & Randall RJ 1951 Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193 265-275.
26. McClenaghan NH & Flatt PR 1999 Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes, Obesity and Metabolism 1 137-150.
27. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW, Swanston-Flatt SK & Flatt PR 1996a Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 1132-1140.
28. McClenaghan NH, Barnett CR, O'Harte FP & Flatt PR 1996b Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. Journal of Endocrinology 151 349-357.
29. Majors A, Ehrhart LA & Pezacka EH 1997 Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arteriosclerosis, Thrombosis and Vascular Biology 17 2074-2081.
30. Malaisse WJ 1991 Physiology of insulin secretion and its alterations in diabetes: the concept of glucotoxicity. In Diabetic Complications: Epidemiology and Pathogenic Mechanisms, pp 3-23. Eds D Andreani, JL Gueriguian & GE Striker. New York, NY, USA: Raven Press.
31. Malaisse WJ 1994 The beta cell in NIDDM: giving light to the blind. Diabetologia 37 S36-S42.
32. 13C isotope isomers. American Journal of Physiology 259 H987-H995.
33. Medina M, Urdiales JL & Amores-Sanchez MI 2001 Roles of homocysteine in cell metabolism: old and new functions. European Journal of Biochemistry 268 3871-3882.
34. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, Kosaka S, Takahashi S & Miyamori I 1999 Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 22 484-490.
35. Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I & Bayindir O 2002 Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Annals of Clinical and Laboratory Science 32 279-286.
36. Prentki M & Corkey BE 1996 Are the beta-cell signalling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45 273-283.
37. Saceda M, Garcia-Morales P, Mato JM, Malaisse WJ & Valverde I 1984 Phospholipid methylation in pancreatic islets. Biochemistry International 8 445-452.
38. Sanchez-Margalet V, Valle M, Ruz FJ, Gascon F, Mateo J & Goberna R 2002 Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. Journal of Nutritional Biochemistry 13 75-79.
39. Seghieri G, Breschi MC, Anichini R, De Bellis A, Alviggi L, Maida I & Franconi F 2003 Serum homocysteine levels are increased in women with gestational diabetes mellitus. Metabolism: Clinical and Experimental 52 724-723.
40. Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH & Schrier RW 1999 Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental 48 1096-1101.
41. Tanaka Y, Gleason CE, Tran PO, Harmon JS & Robertson RP 1999 Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. PNAS 96 10857-10862.
42. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A & Allen RH 1993 Total homocysteine in plasma or serum: methods and clinical applications. Clinical Chemistry 39 1764-1779.
43. Unger RH 1995 Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44 863-870.
44. Unger RH, Zhou YT & Orci L 1999 Regulation of fatty acid homeostasis in cells: novel role of leptin. PNAS 96 2327-2332.
45. Yada T 1994 Action mechanisms of amino acids in pancreatic beta-cells. In Frontiers in Insulin Secretion and Pancreatic Beta-Cell Research, pp 129-134. Eds PR Flatt & S Lenzen. London, UK: Smith-Gordon.